

CHO Cells anti-Human Mosunetuzumab Monoclonal Antibody | anti-CD3e+CD20 antibody

Mosunetuzumab Biosimilar - Research Grade

CATALOG # AAA197056	HOST CHO Cells	REACTIVITY Human	APPLICATIONS Functional Assay
-------------------------------	--------------------------	----------------------------	---


PRODUCT SYNONYMS

Mosunetuzumab; Monoclonal Antibody; Mosunetuzumab Biosimilar - Research Grade; BTCT4465A; anti-CD3e+CD20 antibody


PRODUCT SPECIFICATIONS

Host	CHO Cells
Reactivity	Human
Clonality	Monoclonal
Isotype	Human IgG1-Kappa
Specificity	Detects human CD3/CD20.
Purity/Purification	>95% by SDS-PAGE under reducing conditions >95% by SEC-HPLC test. This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Form/Format	1X PBS, pH7.4, sterile filtered, no preservatives
Concentration	10.71 mg/mL (varies by lot)
Applicable Applications for anti-CD3e+CD20 antibody	FA (Functional Assay)
Target	CD3e/CD20
Extinction Coefficient	1.608
Isotype Note	Bispecific
Endotoxin	<0.1 EU/mg as determined by the LAL method
Dry Ice Note	The product may be shipped with dry ice, and an additional fee may be added to your shipping cost.
Preparation and Storage	Mosunetuzumab biosimilar - Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

IMAGES



SEC-HPLC
The purity of AAA197056 is more than 95% verified by SEC-HPLC.



SDS-PAGE
AAA197056 on SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

ADDITIONAL INFORMATION

Related Product Information for anti-CD3e+CD20 antibody	Mosunetuzumab biosimilar is a bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.
Product Categories/Family for anti-CD3e+CD20 antibody	Low endotoxin; biosimilar antibody; Bispecific

NCBI AND UNIPROT INFORMATION

NCBI GI #	115968
NCBI GeneID	931
UniProt Accession #	P11836; P08984; Q13963; A6NMS4; B4DT24
Molecular Weight	The predicted MW is 49/50/24/23 kDa
NCBI Official Full Name	B-lymphocyte antigen CD20
NCBI Official Synonym Full Names	membrane-spanning 4-domains, subfamily A, member 1
NCBI Official Symbol	MS4A1
NCBI Official Synonym Symbols	B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16
NCBI Protein Information	B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1
UniProt Protein Name	B-lymphocyte antigen CD20
UniProt Gene Name	MS4A1
UniProt Synonym Gene Names	CD20
UniProt Entry Name	CD20_HUMAN

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

